OrbiMed closes sixth flagship fund on $950m

OrbiMed’s most recent investment was earlier this month when it participated in a $53 million Series B financing for ORIC Pharmaceuticals.

ByNathan Williams

22 December 2015•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Managers North America